Takeda and Dr. Reddy’s Laboratories enter an exclusive collaboration to promote and distribute Takeda’s dengue vaccine QDENGA in India. The agreement covers disease awareness activities as well as promotion and distribution, with Dr. Reddy’s leveraging its commercial and healthcare network.
The outlets describe the pact as focused on India’s private vaccination market for both pediatric and adult segments. Coverage also notes that the launch is conditional on local regulatory processes. Multiple reports state QDENGA is expected to become available in the first half of 2027, though the exact timing depends on approvals.
Across sources, the emphasis is largely consistent on the partnership’s purpose—distribution and market rollout rather than clinical trial findings—and on the intended scope within India’s private sector. Differences among outlets are mainly in phrasing and how they summarize the arrangement, with some focusing on the distribution aspect and others highlighting broader promotional efforts ahead of the anticipated 2027 availability.
